title: Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer.
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Monk
authors.forename: Lini N
authors.initials: LN
authors.lastname: Pandite
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D011743:Pyrimidines / Q000008:administration & dosage*; D011799:Quinazolines / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D011743:Pyrimidines; D011799:Quinazolines; D013449:Sulfonamides